Literature DB >> 30464359

A macrolactonization-based strategy to obtain microtuble-stabilizing agent (-)-laulimalide.

Arun K Ghosh1, Yong Wang1.   

Abstract

An alternative synthesis of anti-tumor macrolide (-)-laulimalide is described. The synthesis was achieved utilizing Yamaguchi macrolactonization as the key step. The sensitive C2-C3 cis-olefin functionality has been installed by a macrolactonization of hydroxy alkynic acid and subsequent hydrogenation over Lindlar's catalyst.

Entities:  

Year:  2001        PMID： 30464359      PMCID： PMC6241315          DOI： 10.1016/S0040-4039(01)00436-1

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN： 0040-4039            Impact factor:   2.415


  6 in total

1.  Convenient Preparations of (Diphenylphosphono)acetic Acid Esters and the Comparison of the Z-Selectivities of Their Horner-Wadsworth-Emmons Reaction with Aldehydes Depending on the Ester Moiety.

Authors:  Kaori Ando
Journal:  J Org Chem       Date:  1999-10-29       Impact factor: 4.354

2.  An enantioselective synthesis of the C2-C16 segment of antitumor macrolide laulimalide1.

Authors:  Arun K Ghosh; Yong Wang
Journal:  Tetrahedron Lett       Date:  2002-08-02       Impact factor: 2.415

3.  Synthesis of the macrocyclic core of laulimalide.

Authors:  I Paterson; C De Savi; M Tudge
Journal:  Org Lett       Date:  2001-01-25       Impact factor: 6.005

4.  Synthetic studies of antitumor macrolide laulimalide: a stereoselective synthesis of the C17-C28 segment.

Authors:  Arun K Ghosh; Yong Wang
Journal:  Tetrahedron Lett       Date:  2000-06-22       Impact factor: 2.415

5.  Total Synthesis of (-)-Laulimalide.

Authors:  Arun K Ghosh; Yong Wang
Journal:  J Am Chem Soc       Date:  2000-10-21       Impact factor: 15.419

6.  SYNTHETIC STUDIES OF ANTITUMOR MACROLIDE LAULIMALIDE: ENANTIOSELECTIVE SYNTHESIS OF THE C3-C14 SEGMENT BY A CATALYTIC HETERO DIELS-ALDER STRATEGY.

Authors:  Arun K Ghosh; Packiarajan Mathivanan; John Cappiello
Journal:  Tetrahedron Lett       Date:  2000-03-17       Impact factor: 2.415
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.